The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatment
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-9966
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatment ; volume:38 ; number:1 ; day:21 ; month:10 ; year:2019 ; pages:1-16 ; date:12.2019
Journal of experimental & clinical cancer research ; 38, Heft 1 (21.10.2019), 1-16, 12.2019
- Creator
-
Patties, Ina
Kallendrusch, Sonja
Böhme, Lisa
Kendzia, Eva
Oppermann, Henry
Gaunitz, Frank
Kortmann, Rolf-Dieter
Glasow, Annegret
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13046-019-1434-2
- URN
-
urn:nbn:de:101:1-2020021522500702502526
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:01 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Patties, Ina
- Kallendrusch, Sonja
- Böhme, Lisa
- Kendzia, Eva
- Oppermann, Henry
- Gaunitz, Frank
- Kortmann, Rolf-Dieter
- Glasow, Annegret
- SpringerLink (Online service)
Other Objects (12)
Epigenetic preconditioning with decitabine sensitizes glioblastoma to temozolomide via induction of MLH1
Knockdown of the TP53-induced glycolysis and apoptosis regulator (TIGAR) sensitizes glioma cells to hypoxia, irradiation and temozolomide
GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment
BET inhibitor I-BET151 sensitizes GBM cells to temozolomide via PUMA induction
Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF)
BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression
miR-1297 sensitizes glioma cells to temozolomide (TMZ) treatment through targeting adrenomedullin (ADM)
Retraction Note: BET inhibitor I-BET151 sensitizes GBM cells to temozolomide via PUMA induction
Correction to: Decitabine/Cedazuridine: First Approval
Temozolomide-Perillyl alcohol conjugate impairs Mitophagy flux by inducing lysosomal dysfunction in non-small cell lung Cancer cells and sensitizes them to irradiation
Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1–Survivin axis
The nitric oxide donor JS-K sensitizes U87 glioma cells to repetitive irradiation
Epigenetic preconditioning with decitabine sensitizes glioblastoma to temozolomide via induction of MLH1
Knockdown of the TP53-induced glycolysis and apoptosis regulator (TIGAR) sensitizes glioma cells to hypoxia, irradiation and temozolomide
GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment
BET inhibitor I-BET151 sensitizes GBM cells to temozolomide via PUMA induction
Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF)
BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression
miR-1297 sensitizes glioma cells to temozolomide (TMZ) treatment through targeting adrenomedullin (ADM)
Retraction Note: BET inhibitor I-BET151 sensitizes GBM cells to temozolomide via PUMA induction
Correction to: Decitabine/Cedazuridine: First Approval
Temozolomide-Perillyl alcohol conjugate impairs Mitophagy flux by inducing lysosomal dysfunction in non-small cell lung Cancer cells and sensitizes them to irradiation
Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1–Survivin axis
The nitric oxide donor JS-K sensitizes U87 glioma cells to repetitive irradiation
Epigenetic preconditioning with decitabine sensitizes glioblastoma to temozolomide via induction of MLH1
Knockdown of the TP53-induced glycolysis and apoptosis regulator (TIGAR) sensitizes glioma cells to hypoxia, irradiation and temozolomide
GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment
BET inhibitor I-BET151 sensitizes GBM cells to temozolomide via PUMA induction
Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF)
BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression
miR-1297 sensitizes glioma cells to temozolomide (TMZ) treatment through targeting adrenomedullin (ADM)
Retraction Note: BET inhibitor I-BET151 sensitizes GBM cells to temozolomide via PUMA induction
Correction to: Decitabine/Cedazuridine: First Approval
Temozolomide-Perillyl alcohol conjugate impairs Mitophagy flux by inducing lysosomal dysfunction in non-small cell lung Cancer cells and sensitizes them to irradiation
Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1–Survivin axis